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INTRODUCTION
Thoracic X-ray therapy (XRT) is a com-
mon treatment in the management of
many malignancies. When the field of
XRT involves the heart, injury can result
at several levels (1,2). The pericardium,
myocardium, conduction system, valves
and coronary arteries are subject to dam-
age, leading to a heterogeneous clinical
syndrome (1,2).
The development of more precisely
targeted radiation techniques has re-
duced total radiation dose and volume of
healthy tissues irradiated (1,2). However,
there are still a large number of patients
with breast or lung cancer or mediastinal
lymphoma who have received significant
radiation to the heart in the past or will
continue to receive such radiation expo-
sure in the future; as such, they are at
risk of developing heart disease (1,2).
XRT-induced cardiomyopathy can pres-
ent acutely or remain latent, becoming ev-
ident only years later (1,2). The effects of
XRT are more frequently related to the 
development of a form of restrictive 
cardiomyopathy with a mild reduction in
left ventricular (LV) systolic function and
more pronounced diastolic dysfunction
rather than to a dilated cardiomyopathy
with severe LV systolic dysfunction (3).
In recent years, the development of
murine models has represented a signifi-
cant step forward in the understanding of
the pathophysiology of XRT-induced car-
diomyopathy (4–6). In rodents, a latent
phase after XRT in which the animals
show a preserved cardiac function and
impaired contractile reserve is followed
by a late, chronic phase in which there is
progression of systolic dysfunction asso-
ciated with a worsening in the contractile
reserve and premature death (4).
XRT activates inflammatory pathways
in several cell types, including endothe-
lial cells, macrophages and fibroblasts,
that potentially participate in the initia-
tion and amplification of cardiac toxicity
(7–10). Interleukin (IL)-1 is the prototypi-
cal inflammatory cytokine activated in
response to tissue injury (11–13) and has
been found to be increased in the heart
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and lungs after exposure to ionizing 
radiation (14,15).
The binding of IL-1 to the type I recep-
tor (IL-1R1) induces the synthesis of a
large number of secondary mediators,
largely amplifying the inflammatory re-
sponse and promoting further injury
(11). The role of inflammation and IL-1 in
the initial damage and progression of
XRT-induced cardiomyopathy has not
yet been elucidated.
In experimental animal models, IL-1 in-
duces systolic and diastolic dysfunction
(16,17). IL-1 blockade with anakinra, a re-
combinant human IL-1 receptor antago-
nist (IL-1Ra), provides cardioprotection
and improves LV remodeling and func-
tion after acute myocardial infarction or
doxorubicin-induced injury (18,19). 
Herein, we present the results of an in-
vestigation into the role of IL-1 in the dis-
ease progression in an animal model of
XRT-induced cardiomyopathy (4) by using
mice lacking the IL-1 signaling (IL-1R1
knockout mice [IL-1R1 KO]) and IL-1
pharmacological blockade with anakinra.
MATERIALS AND METHODS
Animals
Female C57BL/6J wild-type (wt) and
IL-1R1 KO mice were purchased from
The Jackson Laboratory (Bar Harbor, ME,
USA) and then bred in the Virginia Com-
monwealth University animal facility.
The IL-1R1 KO mice have a normal phe-
notype at birth and normal development
(20). The mice were housed under condi-
tions of 12-h dark/light cycles and had
access to water and food ad libitum.
Irradiation Protocol
Irradiation of organs with limited re-
generation capacity results in cumulative
damage; therefore, in this study, we chose
to use a simple protocol of a single radia-
tion dose to be able to time the events
starting from a specific time point. The
mice, under light anesthesia (pentobarbi-
tal 30–50 mg/kg; Sigma-Aldrich, St.
Louis, MO, USA), were irradiated using
two different radiation doses, 14 or
20 gray (Gy), to explore a potential dose-
response relationship. Cone beam com-
puted tomography (360 two-dimensional
images at 65 kV, 1 mA) was performed
by using the small animal radiation re-
search platform (SARRP) (Gulmay Med-
ical, Suwanee, GA, USA) to establish the
treatment field. The contrast between the
heart, lungs and surrounding tissues was
reconstructed with the 3D Slicer software
(www.slicer.org), allowing the selection
of the isocenter at the heart and the treat-
ment plan. The dose (14 or 20 Gy), calcu-
lated with the 3D Slicer software, was de-
livered as a static vertical beam by using
a 1.5-cm diameter circular field with the
tube energized to 220 kV, 13.0 mA. After
XRT, mice were injected subcutaneously
with 0.5 mL saline solution (0.9% NaCl)
to avoid dehydration. Body weight was
monitored every 3 d after XRT. The irra-
diated wt and IL-1R1 KO mice were fol-
lowed for up to 6 months after 14 Gy
 irradiation. Significant mortality is ob-
served at 4 months after a radiation expo-
sure of 20 Gy (4). For this reason, the
studies with 20 Gy were terminated at 
4 months. Age-matched sham- irradiated
mice were used as the control group. All
animal experiments were conducted
under the guidelines on humane use and
care of laboratory animals for biomedical
research (21). The study was approved by
the Institutional Animal Care and Use
Committee at the Virginia Common-
wealth University.
Anakinra Treatments
Irradiated wt mice were injected in-
traperitoneally with anakinra, recombi-
nant human IL-1Ra, 10 mg/kg (Swedish
Orphan Biovitrum, Stockholm, Sweden)
or an equal volume (0.2 mL) of saline.
Mice were treated with anakinra every
12 h (to guarantee sustained levels of the
drug over 24 h) for 7 d, starting 24 h be-
fore XRT treatment, with 20 or 14 Gy.
Experimental Groups
The following groups were included in
the study:
(a) sham-wt (wt control), n = 8; 
(b) 20Gy-wt, receiving a single dose of
radiation of 20 Gy, n = 6–12/ group; 
(c) sham-IL-1R1 KO, n = 7; 
(d) 20Gy-IL-1R1 KO, receiving a single
dose of radiation of 20 Gy, n = 6–21/
group; 
(e) 20Gy-wt+anakinra, receiving 20 Gy
and anakinra, n = 5–10/group; 
(f) 14Gy-wt, receiving a single dose of
radiation of 14 Gy, n = 8–11/ group; 
(g) 14Gy-IL-1R1 KO, receiving a single
dose of radiation of 14 Gy n = 10–12/
group; and 
(h) 14Gy-wt+anakinra, receiving 14 Gy
and anakinra, n = 12–17/ group.
Echocardiography
Transthoracic echocardiography 
under light anesthesia (pentobarbital
30–50 mg/kg) was performed at base-
line, 3 d and 4 months by using the Vevo
770 imaging system (VisualSonic,
Toronto, Ontario, Canada) equipped
with a 30-MHz probe as previously de-
scribed (18), according to the American
Society of Echocardiography recommen-
dations (22). At each time point, we mea-
sured the LV end diastolic diameter
(EDD), the LV end systolic diameter
(ESD) and the LV ejection fraction (EF)
(estimated by using the Teicholz for-
mula). To assess the contractile reserve,
mice were injected with 10 ng/mouse
isoproterenol, a β-adrenergic receptor ag-
onist (Sigma-Aldrich), as previously de-
scribed (4). The contractile reserve was
calculated as percentage change in LV
ejection fraction (LVEF) measured 3 min
after isoproterenol injection (LVEFi) and
compared with rest (LVEFr) and calcu-
lated as [(LVEFi – LVEFr)/LVEFr] × 100.
LV Catheterization
To measure the LV pressures, mice
were deeply sedated (pentobarbital,
50–70 mg/kg) and a pressure probe
catheter (Millar Instruments, Houston,
TX, USA) was retrogradely inserted in
the left ventricle through the left carotid
artery. We measured LV end-diastolic
pressure (LVEDP) and –dP/dt, markers
of LV diastolic dysfunction, and the LV
peak pressure (LVPSP) and the +dP/dt,
markers of LV systolic function, in sham
and XRT-treated mice at 4 months (20 Gy)
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and 6 months (14 Gy). The measure-
ments were recorded and analyzed with
the Labchart Pro software (Millar Instru-
ments). After the procedure, the mice
were sacrificed with an overdose of anes-
thetic and the hearts were collected for
additional studies.
Assessment of Myocardial and
Pericardial Fibrosis
Hearts from mice sacrificed at 4 months
(20 Gy) and 6 months (14 Gy) were col-
lected in 10% formalin and then embed-
ded in paraffin as previously described
(23). The 5-μm-thick heart slides were
stained with Masson trichrome (Thermo
Fisher Scientific, Waltham, MA, USA) 
as instructed by the manufacturer to as-
sess total collagen deposition and 
pericardium thickness. ImageJ software
(http://rsb.info.nih.gov/ij/; NIH, Be-
thesda, MD, USA) was used to quantify
the total collagen on total area per field
(expressed as percent collagen on total
area). Perivascular fibrosis was excluded
from this count. Image Pro Plus 6.0 soft-
ware (Media Cybernetics, Rockville, MD,
USA) was used to measure the pericardial
thickness, expressed as percent change
compared with sham- irradiated mice.
Capillary Density
Immunohistochemistry was used to
quantify capillary density on heart tissue
slides by using an antibody raised
against caveolin-1 (Cell Signaling Tech-
nology, Danvers, MA, USA). Staining
with Novared (Vector Laboratories,
Burlingame, CA, USA) was used to de-
tect caveolin-1–positive endothelial cells.
Capillary density was assessed counting
the number of capillaries positive for
caveolin-1 per field (40× magnification).
The measurements were acquired by two
investigators blinded to the treatment 
allocation.
Statistical Analysis
Statistical analysis was performed by
using SPSS 15.0. Continuous variables
were expressed as mean and standard
error. Two-way analysis of variance was
used to compare treated and control val-
ues between two or more groups by using
the time-group interaction. A t test for un-
paired data was used to compare two
groups, and one-way analysis of variance
was used to compare unpaired data be-
tween three or more groups. Unadjusted
two-tailed P values <0.05 were considered
statistically significant. Kaplan-Meier sur-
vival curves were created, and the log-
rank test was used to compare survival
among the different groups.
All supplementary materials are available
online at www.molmed.org.
RESULTS
Dose-Response Effects of Radiation
The mice showed dose-response effects
when irradiated with two different doses
of radiation (20 or 14 Gy). XRT induced a
dose-dependent reduction in the contrac-
tile reserve at 72 h and 4 months, mea-
sured as the percentage change in LVEF
after isoproterenol injection (Figure 1).
XRT also induced a dose-dependent de-
crease in the LVEF (Figure 1) and increase
in LVEDP (Figure 1). The significant in-
crease in LVEDP with XRT 20 Gy was not
associated with changes in LVPSP or in
+dP/dt and –dP/dt (Table 1), reflecting an
increase in LV stiffness or elastance, rather
than impairment in active relaxation.
Effects of IL-1 Signal Blockade on
Acute Myocardial Damage
IL-1R1 KO mice, which are not respon-
sive to IL-1, were also irradiated with the
two doses of XRT (20 or 14 Gy). The im-
pairment in contractile reserve, at 72 h
after XRT, seen in the wt mice, was sig-
nificantly blunted in IL-1R1 KO mice
(Figures 2, 3). Treatment of irradiated wt
mice with anakinra, used to simulate a
therapeutic intervention, led also to a
preservation of the contractile reserve 
72 h after XRT (Figures 2, 3).
Effects of IL-1 Signal Blockade on 
RT-Induced Cardiomyopathy
IL-1R1 KO mice had no significant re-
duction in baseline LVEF and a milder
reduction in contractile reserve after XRT
(Figure 4). Treatment with anakinra for 
7 d preserved LVEF and contractile re-
serve at 3 d, but the benefits were no
longer seen at 4 months (Figure 4).
No significant differences were ob-
served in the LV diameters comparing
the different groups of mice (Supplemen-
tary Table S1).
Effects of IL-1 Signal Blockade on LV
Hemodynamic
A significant increase in LVEDP after
XRT 20 Gy was also seen in the IL-1R1
KO mice and in wt mice treated with
anakinra (Figure 5). These results high-
light the dissociation between LV con-
tractile function and stiffness. Supple-
mentary Figure S1 and Table 2 show data
regarding hemodynamic measurements
in the XRT 14 Gy group.
Effects of IL-1 Signal Blockade on
Fibrosis and Capillary Density
The reparative fibrosis after injury may
be responsible for increased cardiac stiff-
ness (24). Quantification of fibrosis in the
myocardium and pericardium revealed
an increase in collagen deposition after
XRT 20 Gy in the wt mice, as well as in
IL-1R1 KO mice or in the wt mice treated
with anakinra (Figure 6). This scenario
supports the dissociation between LV
contractile function and fibrosis causing
increased stiffness. XRT 14 Gy induced a
milder increase in fibrosis (Supplemen-
tary Figure S2).
Radiation induced damage to the 
microvasculature reflected in a mild 
reduction in capillary density in the 
wt 20 Gy– treated mice; therefore, no
significant improvements were ex-
pected in the IL-1R1 KO mice (Supple-
mentary Figure S3).
Effects of IL-1 Signal Blockade on
Survival
A marked increase in mortality was
seen at 4 months after XRT 20 Gy in
both wt and IL-1R1 KO mice (Figure 7).
Treatment of wt mice with anakinra had
no significant effect on survival after
XRT 20 Gy, with a survival curve super-
imposed to that of the IL-1R1 KO mice.
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All mice irradiated with 14 Gy (100% 
of wt and IL-1R1 KO) survived to 
6 months, as did all the sham-irradiated
mice.
DISCUSSION
XRT-induced cardiomyopathy is a het-
erogeneous disease characterized by a
dose-dependent progressive impairment
in contractile reserve and a decrease in
LV systolic function, an increase cardiac
stiffness due to myocardial and pericar-
dial fibrosis, and premature death
(4,24–26). The mechanisms involved in
the progression of systolic dysfunction
and fibrosis are incompletely under-
stood. The results of this study show that
IL-1 amplifies myocardial injury after
XRT and mediates the reduction of con-
tractile reserve and LV systolic function.
Genetic and pharmacological blockade of
IL-1, indeed, limited the degree of injury,
measured as preserved contractile re-
serve and LV systolic function up to 4
months after XRT. IL-1 blockade, how-
ever, did not protect from the develop-
ment of myocardial and pericardial fibro-
sis and premature death associated with
high dose (20 Gy) XRT, thus showing
that IL-1 mediates some but not all the
processes associated with XRT-induced
cardiomyopathy.
IL-1 is a key inflammatory mediator
involved in the amplification of the tis-
sue inflammatory response (11–13). IL-1β
is synthesized as an inactive precursor
(pro-IL-1β) that is cleaved by caspase-1
following formation of the inflamma-
some consequent to tissue injury, as fol-
lowing XRT (11–13,27,28). The activation
of the inflammasome pathway may be
due to the production of reactive oxygen
species after exposure to ionizing radia-
tion or to the production or release of
damage-associated molecular patterns by
irradiated cells (27–30). Activation of the
inflammasome then leads to IL-1β pro-
cessing and release, and inflammatory
cell death, leading to amplification of the
inflammatory response and injury (31).
Recent studies have highlighted the in-
volvement of IL-1 signaling in heart dis-
ease (13). IL-1 has been shown to induce
impairment in β-adrenergic responsive-
ness and contractility, both in vitro and in
vivo (16,32). Single or repeated injections
of recombinant murine IL-1β induce sys-
tolic dysfunction and impaired contrac-
tile reserve in absence of structural
changes (16,33).
Injury to the heart during irradiation
leads to an inflammatory response (6,34).
We hypothesized that IL-1 mediated the
inflammatory response and the progres-
sion of the cardiomyopathy. Accordingly,
in our mouse model, XRT induced myo-
cardial injury and impaired the contrac-
tile reserve, measured as response to 
β-adrenergic receptor stimulation, and
the resting LV systolic function in the wt
mice, yet this effect was not seen in the
Figure 1. Dose-response effects of XRT. Mice receiving two different doses of radiation
in a single treatment (20 or 14 Gy) showed a dose-response effect at echocardiogra-
phy and with hemodynamic measurements. (A) Contractile reserve assessed at 72 h
after receiving XRT treatments (20 or 14 Gy) as a change in left ventricular ejection
fraction (LVEF) measured at rest and 3 min after isoproterenol injection. (B) LVEF at
rest, measured 4 months after XRT and expressed as percentage reduction versus
sham. (C, D) Contractile reserve assessed and LVEDP measured at 4 months after XRT.
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IL-1R1 KO mice, and it could be pre-
vented by pharmacological IL-1 blockade
with anakinra.
The genetic deletion of the IL-1R1 and
the treatment with anakinra should pro-
duce the same effect. The differences be-
tween IL-1R1 KO mice and anakinra-
treated mice may be related to the
following: (a) the small sample size; (b) a
short period of pharmacological inter-
vention with anakinra versus the perma-
nent deletion of the IL-1RI gene (that is,
7 d of treatment lead to cardioprotection
in the acute phase that was lost 4 months
after); (c) binding of anakinra to IL-1RII,
a decoy receptor that is not expected to
affect outcomes but may sequester IL-
1Ra; (d) intracellular effects of IL-1Ra in-
dependent of the IL-1R1 (35); and (e) in-
complete deletion of the IL-1R1
expression in some strains of IL-1R1 KO
mice due to the expression of a short-
ened gene product in lung vasculature,
as previously reported (36).
Anakinra treatment for 7 d was chosen
after considering prior results in the
mouse model of AMI. In this model, we
found that time of treatment was suffi-
cient to reduce adverse remodeling in the
long term without rebound effects due to
interruption of the treatment (37,38).
However, considering that anakinra pre-
served the contractile reserve at 3 d but
not at 4 months, we speculate that a
longer treatment with anakinra may be
needed.
Although there was a reduction in the
LV systolic function at rest in the irradi-
ated wt mice, we did not observed a de-
crease in +dP/dt. The difference may re-
side in the different loading dependence
on the two techniques: invasively mea-
sured +dP/dt is more preload depen-
dent and the LVEF is more afterload 
dependent.
IL-1 blockade was not sufficient to pre-
vent the increase in myocardial and peri-
cardial fibrosis or to improve survival
after high-dose XRT. In models of acute
myocardial infarction (AMI), genetic or
pharmacological inhibition of IL-1 re-
duces LV dysfunction, limits the adverse
remodeling process and has no effects on
myocardial fibrosis, yet reduces mortal-
ity (18,20,39–42). There appear to be sim-
ilarities and differences in the role of IL-1
in the ischemic and XRT-induced car-
diomyopathy. We suspect that the dis-
crepancies between ischemic injury and
XRT-induced cardiomyopathy may be re-
lated to differences in their respective
pathophysiology. The cause of death in
mice with AMI is mostly due to cardiac
rupture or pump failure occurring early
during the course (43). The effects of fo-
cused irradiation of the heart in female
mice using the SARRP irradiator are
overall comparable to those previously
reported by our group using a clinical ra-
diation machine with a broader beam
shielding the mice with lead and leaving
only the chest exposed to the radiations
(4). The cause of death in mice after XRT
is less clear. Death occurs late in the course
and is not associated with cardiac rup-
ture or with a severe reduction in systolic
function (4). Consequently, such death
may be cardiac because of an arrhythmic
cause or non–cardiac-associated because
of injury to other organs such as the
lungs or esophagus. The injury from XRT
originates from the epicardial surface,
and these mice experience injury to the
Table 1. Hemodynamic parameters.
LVPSP LVEDP +dP/dt –dP/dt 
Groupa (mmHg) (mmHg) (mmHg/s) (mmHg/s)
Sham-wt 66.3 ± 3.7 3.6 ± 0.5 +3,708 ± 205 –3,375 ± 279
Sham-IL-1R1 KO 57.3 ± 2.3 2.4 ± 0.4 +2,975 ± 210 –2,900 ± 247
20Gy-wt 67.5 ± 2.2 7.8 ± 1.0b +3,450 ± 319 –3,225 ± 248
20Gy-IL-1R1 KO 63.6 ± 2.6 8.1 ± 4.2c +3,528 ± 985 –2,500 ± 658
20Gy-wt+anakinra 72.2 ± 3.1 9.1 ± 2.7b +3,650 ± 650 –2,750 ± 450
aSee Experimental Groups in Materials and Methods for information on the groups.
bP < 0.05 versus sham-wt.
cP = 0.05 versus sham-IL-1RI KO. 
Figure 2. IL-1 blockade prevents reduc-
tion in contractile reserve 72 h after 
20-Gy XRT. Contractile reserve was as-
sessed 72 h after receiving 20-Gy XRT
treatment as a change in LVEF measured
at rest and 3 min after isoproterenol 
injection.
Figure 3. Genetic deletion of IL-1R1 pre-
vents reduction in contractile reserve 72 h
after 14-Gy XRT. Contractile reserve, as-
sessed as a change in LVEF measured at
rest and 3 min after isoproterenol injec-
tion was measured at 72 h in mice after
receiving a 14-Gy single radiation dose.
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heart in a distance-dependent manner; as
such, it is not surprising that the most
evident effect is the pericardial fibrosis in
this model (6), whereas in the AMI
model, the ischemic injury initiates from
the endocardium. Therefore, subendocar-
dial and transmural myocardial fibrosis
is seen, but epicardial or pericardial fi-
brosis occurs rarely and only when the
injury is transmural (44). The marked 
increase in LV end diastolic pressure in
the absence of changes in –dP/dt sug-
gests increased cardiac stiffness (reduced
compliance), as with a mechanical obsta-
cle to filling that is consistent with peri-
cardial constriction or myocardial restric-
tion due to epicardial fibrosis (45). In pa-
tients, the cardiomyopathy associated
with XRT indeed presents more like a re-
strictive cardiomyopathy or constrictive
pericarditis (with small LV volumes,
rather preserved LVEF, and markedly
impaired diastolic function) than with 
dilated cardiomyopathy with systolic
dysfunction (3).
Therefore, the mechanisms leading to
myocardial and pericardial fibrosis re-
main unclear. The inflammatory re-
sponse after radiation injury can have
multiple components with a systemic
“cardiodepressant” effect distinct from
the fibrotic effect. We cannot exclude
that the fibrotic effects could be medi-
ated by another product of the inflam-
masome IL-18 (12). IL-18 is a member of
the IL-1 family of cytokines and is con-
stitutively expressed in several cell
types, but it increases during inflamma-
tion, cellular stress and tissue injury
(46,47). IL-18, by binding to its receptor
(IL-18R), activates downstream signals
that are common to the IL-1 and TLR
pathways; however, the activation of the
IL-18R and IL-1R1 receptors has differ-
ent effects (12,46,48,49). Daily injections
of IL-18 induce myocardial fibrosis in
the mouse (50,51). As a product of the
Figure 4. IL-1 blockade prevents XRT-induced cardiomyopathy. Four months after XRT
(14 or 20 Gy), the mice underwent echocardiography to measure LVEF at rest and 
3 min after β-adrenergic stimulation (contractile reserve). (A, B) LVEF at rest measured 
4 months after XRT (20 or 14 Gy, respectively) expressed as percentage reduction ver-
sus sham. (C, D) Contractile reserve measured at 4 months after XRT (20 and 14 Gy, 
respectively).
Figure 5. LV hemodynamic measurements.
Measure of LVEDP in the groups of mice
treated with 20-Gy XRT.
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inflammasome, IL-18 may therefore
have a complementary effect with IL-1
on the heart in mediating XRT-induced
cardiomyopathy. Further studies are
needed to evaluate the effect of IL-18
blockade or inhibitors of the inflamma-
some in XRT-induced cardiomyopathy.
Despite the fact that IL-1 blockade
failed to rescue the mice from cardiac fi-
brosis and premature death due to high-
dose radiation (20 Gy), IL-1 blockade (ge-
netic or pharmacologic) limited acute
cardiac injury and preserved cardiac con-
tractile function in mice. This result was
particularly evident in mice with less in-
jury to the heart due to a lower radiation
dose (14 Gy). With improvements in XRT
treatment planning (for example, inten-
sity modulated therapy), injury to the
heart is less common and is in less severe
forms. Acute or constrictive pericarditis
commonly seen in the early days of ra-
diotherapy is now rarely seen (3).
Nonetheless, the excess incidence of
heart failure in patients who have re-
ceived chest irradiation persists to cur-
rent times and is only in part explained
by accelerated coronary atherosclerosis
(3). Chronic inflammation, measured 
by inflammatory markers, such as the 
C-reactive protein, is considered a risk
factor for cardiovascular diseases, and
several studies showed an association
between radiation and chronic inflamma-
tion (52–54). Mice treated with XRT 14 or 
20 Gy experienced a significant reduction
in contractile reserve as early as 3 d after
XRT, which was progressive over time.
An impairment in contractile reserve cor-
relates with exercise intolerance and
symptoms of heart failure (16).
The finding that IL-1 mediates the re-
duction in contractile reserve observed
with XRT-induced cardiomyopathy sug-
gests that IL-1–targeted strategies may be
useful in limiting myocardial injury
acutely and potentially prevent late onset
of heart failure. Impaired exercise toler-
ance/fatigue is the most common symp-
tom in patients with systolic and dias-
tolic heart failure, and a recent study has
shown a significant improvement in
peak aerobic exercise capacity reflecting
an improved contractile reserve is evi-
dent after a short course of treatment
with IL-1 blockers (16,55). Reduced exer-
cise capacities has been associated with
abnormal heart rate recovery in cancer
patients 20 years after thoracic radiation
treatment (56). Furthermore, inflamma-
tory markers correlate with fatigue dur-
ing radiation therapy in patients with
cancer (57). Whether IL-1–targeted strate-
gies will be tolerated in patients receiv-
ing irradiation for cancer or whether
such strategies will interfere with the
cancer-killing properties of the irradia-
tion is unknown and will require further
study. Of interest, several studies are ex-
ploring IL-1–targeted strategies as can-
cer-treating strategies, and as such, IL-1
blockade may prove to serve a dual func-
tion of cardiac protection and cancer
treatment (58–60).
However, the study reported herein is
not free of limitations. (a) The response
of the healthy mice to XRT injury may
differ from that seen in mice with cancer,
and may differ even more from that in
patients with cancer. As such, translation
should be considered with caution. (b)
Although the presence of impaired con-
tractile reserve preceding LV systolic
dysfunction and the cardiac fibrosis re-
semble many aspects of the clinical syn-
drome of XRT-induced cardiomyopathy
in patients, other aspects (that is, acceler-
ated atherosclerosis) are not explored in
this model. (c) While we show clear evi-
dence of enhanced IL-1 activity mostly
through evidence of benefit from genetic
Figure 6. IL-1 blockade had no effects on
myocardial and pericardial fibrosis. Mas-
son’s trichrome was used to assess the
total amount of interstitial collagen and
the pericardial fibrosis at 4 months (20 Gy)
after XRT. (A) Quantification of the myo-
cardial interstitial fibrosis in wt mice,
anakinra-treated mice and IL-1RI KO
mice. (B) Representative images of the
pericardial thickness in sham and wt or 
IL-1RI KO mice. (C) Quantification of the
pericardial thickness in the groups of
sham and 20 Gy irradiated mice.
Anakinra-treated groups were compared
with the sham-wt group.
Figure 7. Survival curve. Kaplan-Meyer
curves were used to evaluate the survival
rate in wt and IL-1R1 KO mice 4 months
after receiving XRT treatment.
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and pharmacological IL-1 blockade, we
do not provide direct measurements of
IL-1β or IL-1α in the heart of irradiated
mice, since it is not uncommon to have
undetectable tissue or plasma levels de-
spite clear evidence of increased IL-1 ac-
tivity. (d) We based our conclusions on
the findings of “loss of function” strate-
gies (IL-1R1 KO and antagonist) and
have not used a “gain of function” ap-
proach in which IL-1 activity is en-
hanced, such as the IL-1 receptor antago-
nist (IL-1Ra) KO (20). (e) By using IL-1R1
KO mice or anakinra as IL-1–blocking
strategies, we were unable to distinguish
between the specific effects of IL-1β or
IL-1α on the observed phenotype. (f) IL-1
affects contractility through multiple and
nonexclusive mechanisms affecting intra-
cellular calcium and calcium-sensitivity
(13), and we have not explored which
mechanism is specifically involved in ra-
diation-induced cardiomyopathy. (g) The
blockade of IL-1 signaling did not affect
the survival rate. (h) We limited our
analysis to the heart and did not include
other organs in which the role of IL-1
may be different (61).
CONCLUSION
IL-1 blockade preserves LV contractile
reserve and systolic function after XRT
(14–20 Gy) in the mouse. However, IL-1
blockade fails to rescue the mouse from
severe myocardial and pericardial fibro-
sis and premature death in the mouse
undergoing high-dose XRT (20 Gy).
These data indicate that IL-1 mediates
some but not all the processes involved
in the progression of XRT-induced car-
diomyopathy. As such, we may foresee
IL-1 blockade to improve some aspects of
the disease in cancer patients undergoing
radiation therapy (that is, exercise intol-
erance, fatigue) but not others (that is,
constrictive pericarditis in patients
treated with high doses of XRT) (56,57).
The timing of IL-1 blockade in relation to
cancer treatment needs to be clarified be-
fore one can design a clinical trial in this
area, and additional studies on the
pathogenesis of XRT-induced cardiomy-
opathy are needed.
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